First Hawaiian Bank Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

First Hawaiian Bank raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 556.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,159 shares of the medical device company's stock after purchasing an additional 19,629 shares during the quarter. First Hawaiian Bank's holdings in DexCom were worth $1,801,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Private Advisor Group LLC boosted its position in shares of DexCom by 9.1% during the second quarter. Private Advisor Group LLC now owns 10,710 shares of the medical device company's stock valued at $1,214,000 after purchasing an additional 891 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of DexCom by 206.4% in the 2nd quarter. Acadian Asset Management LLC now owns 24,539 shares of the medical device company's stock worth $2,778,000 after acquiring an additional 16,531 shares in the last quarter. Caprock Group LLC lifted its position in DexCom by 38.1% during the 2nd quarter. Caprock Group LLC now owns 8,595 shares of the medical device company's stock valued at $975,000 after acquiring an additional 2,370 shares during the period. Quest Partners LLC boosted its stake in DexCom by 473.8% during the second quarter. Quest Partners LLC now owns 4,298 shares of the medical device company's stock worth $487,000 after acquiring an additional 3,549 shares in the last quarter. Finally, Prudential PLC grew its holdings in DexCom by 38.6% in the second quarter. Prudential PLC now owns 13,545 shares of the medical device company's stock worth $1,536,000 after purchasing an additional 3,769 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DXCM traded up $0.74 during trading hours on Thursday, hitting $80.09. The stock had a trading volume of 2,423,035 shares, compared to its average volume of 2,644,387. The firm has a market capitalization of $31.28 billion, a PE ratio of 47.96, a PEG ratio of 2.46 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a fifty day moving average price of $76.78 and a 200 day moving average price of $79.52.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group raised their price target on DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a report on Monday, December 9th. Raymond James dropped their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Finally, Oppenheimer cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $98.00.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.